MET contributes specifically to erlotinib resistance in head and neck squamous cell carcinoma (HNSCC) with activated SRC, where MET activation is dependent on SRC phosphorylation, providing an alternate survival pathway. Here, MET is linked to head and neck squamous cell carcinoma.